When was NCIMB founded?

NCIMB was founded in 1982 and raised its 1st funding round 26 years after it was founded.

Where is NCIMB located?

NCIMB is headquartered in United Kingdom. It is registered at . WELLHEADS PLACE,DYCE,ABERDEEN,SCOTLAND,AB21 7GB.

How many employees does NCIMB have?

As of Jul 31, 2024, the latest employee count at NCIMB is 25.

Is NCIMB a funded company?

NCIMB is a funded company, having raised a total of $2.27M across 3 funding rounds to date. The company's 1st funding round was a $***** Unattributed round, raised on 2008.

When was the latest funding round of NCIMB?

NCIMB's latest funding was a $***** Unattributed round on Apr 29, 2025, with participation from 2 investors. Its primary sector is Biopharma Outsourcing. Globally, the Biopharma Outsourcing sector has seen $283M in funding in 2026 to date.

Where does NCIMB rank among its competitors?

NCIMB ranks 8th amongst 386 active competitors, of which 21 are funded. It stands 4th in terms of total funding among its competitors. The most recent competitor to raise funding was AFYREN, which secured $8.25M in Feb, 2026.

Who are the top competitors of NCIMB?

NCIMB's top competitors include Nordic Bioscience, AFYREN and BioAgilytix. Among them, AFYREN secured the most recent funding round in February, 2026.

NCIMB - 2026 Company Profile, Team, Funding & Competitors

Company Details

Provider of biorepository, microbial culture collection and microbiology services. It offers microbiology, chemical analysis and biomaterial storage services to clients from the pharmaceutical, personal care, oil and gas, food, agriculture and environment industries, as well as from academia. The services include microbial identification, patent deposits, biomaterial storage, freeze drying, oilfield microbiology, toxicity testing, analytical services, and R&D support.

Website: www.ncimb.com/
Social
Phone Number: +44 **********
Registered Address: . WELLHEADS PLACE,DYCE,ABERDEEN,SCOTLAND,AB21 7GB

Key Metrics

Founded Year

1982

Location

United Kingdom

Stage

Early Stage

Total Funding

$2.27M in 3 rounds

Latest Funding Round

Unattributed, Apr 29, 2025, $*****

Investors

The Scottish National Investment Bank & 3 more

Ranked

8^th among 386 active competitors

Employee Count

25 as on Jul 31, 2024

Investment & Acquisitions

Enterobiotix

Similar Companies

AFYREN & 61 more

View NCIMB's full profile

NCIMB is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Ncimb Limited CIN: SC078368 , United Kingdom, Active	Apr 19, 1982	$2.55M (As on Jul 31, 2023)	25 (As on Jul 31, 2024)

NCIMB has raised a total funding of $2.27M over 3 rounds. Its first funding round was on 2008. Its latest funding round was a Unattributed round on Apr 29, 2025 for $*****. 2 investors participated in its latest round. NCIMB has 4 institutional investors.

Here is the list of recent funding rounds of NCIMB:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Apr 29, 2025	5424833	Unattributed	2678040	6359214	9894409	7603988
Dec 01, 2020	5830374	Grant (prize money)	8673290	3763802	4039886	Europa
2008	7273	Unattributed	1900	1930	8587	E-Synergy

Access funding benchmarks and valuations. Sign up today!

View details of NCIMB's funding rounds and investors

NCIMB's employee count trend

NCIMB has 25 employees as of Jul 24. The total employee count is 7.0% lower than what it was in Jul 23. Here is NCIMB's employee count trend over the years:

Uncover NCIMB's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of NCIMB include Nordic Bioscience, AFYREN and BioAgilytix. Here is the list of Top 10 competitors of NCIMB, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Nordic Bioscience 1996, Herlev (Denmark), Late Stage	Preclinical and clinical drug development CRO with proprietary in-house Biomarker platform	-	KKR, Europa	62/100
2nd	AFYREN 2012, Paris (France), Public	Provider of analytical services for microbiology, chemistry and bioprocesses industries	$132M	Kemin, Valquest Capital Management & 11 others	61/100
3rd	BioAgilytix 2008, Durham (United States), Acquired	Global bioanalytical services leader, supporting drug development across various modalities	-	GHO Capital Partners, Caledonia Private Capital ... & 2 others	60/100
4th	Solvias 1999, Kaiseraugst (Switzerland), Acquired	Developer and manufacturer of medical devices, cosmetics, agrochemicals, and chemicals	-	Water Street, Broadoak Capital Partners & 1 others	58/100
5th	Perfectus Biomed 2012, Daresbury (United Kingdom), Acquired	Provides services for research-based approach for microbiological testing	$765K	Northern Powerhouse Investment Fund, Future Planet Capital ... & 4 others	58/100
6th	Spore Biotechnologies 2022, Paris (France), Series A	Developer of microbial detection technology for life science industries	$35M	LocalGlobe, Singular & 13 others	53/100
7th	Advion 1993, Ithaca (United States), Acquired	Mass spectrometry, chromatography, and purification solutions for scientific advancement	$45.6M	Aisling Capital, Polaris Partners & 3 others	50/100
8th	NCIMB 1982, United Kingdom, Early Stage	Provider of biorepository, microbial culture collection and microbiology services	$2.27M	The Scottish National Investment Bank, Maven Capital Partners ... & 2 others	49/100
9th	Alderley Analytical 2013, Stockport (United Kingdom), Acquired	Provider of bioanalytical services for drug development programs and testing	$869K	Northern Powerhouse Investment Fund, Pioneer Group ... & 3 others	49/100
10th	Kcas Bioanalytical Services 2014, Shawnee (United States), Acquired	Global bioanalytical CRO providing comprehensive drug development services and advanced assay capabilities	-	-	49/100